Functional FGFR4 Gly388Arg Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 28

PMID 28445975

Citations 10

Authors

Si-Wei Xiong

Jianqun Ma

Fen Feng

Wen Fu

Shan-Rong Shu

Tianjiao Ma

Caixia Wu

Guo-Chang Liu

Jinhong Zhu

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor receptor 4 (FGFR4) is a member of receptor tyrosine kinase family. A functional Gly388Arg (rs351855 G>A) polymorphism in FGFR4 gene causes a glycine-to-arginine change at codon 388 within the transmembrane domain of the receptor. Although the FGFR4 rs351855 G>A polymorphism has been implicated in cancer development, its association with cancer risk remains controversial. Here, we have systematically analyzed the association between the rs351855 G>A polymorphism and cancer risk by performing a meta-analysis of 27 studies consisting of 8,682 cases and 9,731 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. The rs351855 G>A polymorphism was associated with an increased cancer risk under the recessive model (OR=1.19, 95% CI=1.01-1.41). Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer. This meta-analysis demonstrates the FGFR rs351855 G>A polymorphism is associated with increased cancer risk and suggests it could potentially serve as a chemotherapeutic target or biomarker to screen high-risk individuals.

Citing Articles

FGFR4-driven plasticity in breast cancer progression and resistance to therapy.

Braun M, Piasecka D, Sadej R, Romanska H Br J Cancer. 2024; 131(1):11-22.

PMID: 38627607 PMC: 11231301. DOI: 10.1038/s41416-024-02658-y.

Association of the rs1966265 and rs351855 Variants with Colorectal Cancer in a Mexican Population and Their Analysis In Silico.

Carrillo-Davila I, Garibaldi-Rios A, Figuera L, Gomez-Meda B, Zuniga-Gonzalez G, Puebla-Perez A Biomedicines. 2024; 12(3).

PMID: 38540215 PMC: 10968131. DOI: 10.3390/biomedicines12030602.

Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma.

Rock A, Uche A, Yoon J, Agulnik M, Chow W, Millis S J Pers Med. 2023; 13(10).

PMID: 37888109 PMC: 10608227. DOI: 10.3390/jpm13101499.

Proteogenomic links to human metabolic diseases.

Koprulu M, Carrasco-Zanini J, Wheeler E, Lockhart S, Kerrison N, Wareham N Nat Metab. 2023; 5(3):516-528.

PMID: 36823471 PMC: 7614946. DOI: 10.1038/s42255-023-00753-7.

A rare case of highly differentiated follicular carcinoma in ovary with FGFR4 Gly388Arg polymorphism: a case report and literature review.

Bao Y, Wang C, Huang W, Yao L, Yuan L J Ovarian Res. 2022; 15(1):71.

PMID: 35701820 PMC: 9195278. DOI: 10.1186/s13048-022-01007-y.

References

Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A . Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003; 98(10):2245-50. DOI: 10.1002/cncr.11778. View

Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A . Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004; 111(2):213-7. DOI: 10.1002/ijc.20204. View

Naidu R, Har Y, Taib N . Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res. 2010; 18(2-3):65-71. DOI: 10.3727/096504009789954609. View

Ho H, Pok S, Streit S, Ruhe J, Hart S, Lim K . Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2008; 50(1):118-27. DOI: 10.1016/j.jhep.2008.08.015. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Saichaemchan S, Ariyawutyakorn W, Varella-Garcia M . Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med. 2015; 16(1):40-62. DOI: 10.2174/1566524016666151222144231. View

Li S, Dai Q, Chen S, Zhang S, Liao X, Deng X . Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol. 2013; 35(4):3905-15. DOI: 10.1007/s13277-013-1519-z. View

Johnston C, Cox H, Gomm J, Coombes R . bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. Biochem J. 1995; 306 ( Pt 2):609-16. PMC: 1136561. DOI: 10.1042/bj3060609. View

Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M . Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002; 62(3):840-7. View

10.

Sahadevan K, Darby S, Leung H, Mathers M, Robson C, Gnanapragasam V . Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol. 2007; 213(1):82-90. DOI: 10.1002/path.2205. View

11.

Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattner S . Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res. 2012; 72(22):5767-77. PMC: 5455878. DOI: 10.1158/0008-5472.CAN-11-3654. View

12.

Wang J, Stockton D, Ittmann M . The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004; 10(18 Pt 1):6169-78. DOI: 10.1158/1078-0432.CCR-04-0408. View

13.

Xue W, He Y, Zhu J, Ma J, He J, Jia W . Association of BRCA2 N372H polymorphism with cancer susceptibility: a comprehensive review and meta-analysis. Sci Rep. 2014; 4:6791. PMC: 4210867. DOI: 10.1038/srep06791. View

14.

Tanuma J, Izumo T, Hirano M, Oyazato Y, Hori F, Umemura E . FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep. 2010; 23(3):739-44. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

16.

Eswarakumar V, Lax I, Schlessinger J . Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16(2):139-49. DOI: 10.1016/j.cytogfr.2005.01.001. View

17.

Schwertfeger K . Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets. 2009; 10(7):632-44. DOI: 10.2174/138945009788680419. View

18.

Shen Y, Lu Y, Shen D, Liu Y, Su X, Zhu G . Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients. World J Gastroenterol. 2013; 19(28):4568-75. PMC: 3725383. DOI: 10.3748/wjg.v19.i28.4568. View

19.

Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S . Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008; 123(11):2574-9. DOI: 10.1002/ijc.23578. View

20.

Hallinan N, Finn S, Cuffe S, Rafee S, OByrne K, Gately K . Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016; 46:51-62. DOI: 10.1016/j.ctrv.2016.03.015. View